Cutia Therapeutic’s CU-20401 Shows Promising Safety and Efficacy in Phase I Abdominal Fat Reduction Study
Cutia Therapeutic (HKG: 2487), a China-based dermatology specialist, has announced the successful completion of a...
Obesity
Zhongsheng Pharmaceutical Initiates Phase II Trials for Polypeptide Drug RAY1225 in Diabetes and Obesity
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced the initiation...
Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024
Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20%...
Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity
Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive...
Joincare Pharmaceuticals Gets Green Light for Semaglutide Biosimilar Clinical Trial
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical entity, has announced that...
Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales
Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for...
Junde Pharmaceuticals Licenses Weight-Reducing Capsule JTX-102 to Changchun GeneScience
Xiamen Junde Pharmaceutical Technology Co., Ltd., a China-based pharmaceutical company, has entered into a licensing...
Sanofi CEO Paul Hudson Rules Out GLP-1 Competition, Eyes Next-Gen Weight-Management Therapies
Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company...
Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces...
Servier Faces $475 Million Penalty Over Banned Antidiabetic Drug Mediator in France
French pharmaceutical company Servier has been ordered by a French court to pay €430.6 million...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment
Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first...
Eli Lilly Teams Up with Fauna Bio to Uncover New Anti-Obesity Drug Targets
Eli Lilly (NYSE: LLY) has entered a collaboration agreement with fellow U.S. firm Fauna Bio...
Novo Nordisk Acquires Alkermes’ Irish Production Site for $92.5 Million to Boost GLP-1 Output
Novo Nordisk (CPH: NOVO-B), a Danish pharmaceutical giant, has reached an agreement to acquire a...
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...
Pfizer’s Danuglipron Phase IIb Trial Achieves Weight Loss Goals Amid Tolerability Concerns
Pfizer (NYSE: PFE) announced last week that its Phase IIb trial evaluating danuglipron, a glucagon-like...
Novo Nordisk Sets February 2024 Launch for Wegovy in Japan, Expanding into Asia
Novo Nordisk (CPH: NOVO-B), headquartered in Denmark, has announced that it will launch its anti-obesity...
Novo Nordisk Invests DKK 16 Billion to Expand French Production Facility
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has initiated an expansion of its production facility...
Belgium Bans Ozempic for Weight Loss as Global Shortage Persists
Belgium has issued a royal decree prohibiting the use of Novo Nordisk’s (NYSE: NVO) diabetes...
Eli Lilly’s Zepbound Approved by FDA for Chronic Weight Management in Adults
Eli Lilly (NYSE: LLY) has received registration approval from the US Food and Drug Administration...
AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third...